BioProtonics

BioProtonics is a medical imaging technology company based in Santa Barbara, California, focused on advancing magnetic resonance imaging (MRI) to detect diseases at earlier stages. The company describes itself as transforming MRI to better detect early stages of disease and positions its core innovation, Magnetic Resonance Histopathology (MRH), as a non-invasive digital biopsy. MRH is a software-based MRI method that measures tissue texture at the microscopic level, at scales below one millimeter, by using a proprietary MRI pulse sequence that targets specific spatial wavelengths. According to the company, this approach provides insight into tissue microarchitecture and structural differences that can help radiologists identify signs of early cancer or other diseases. The company's value proposition centers on offering a safer, less invasive, more accurate, and potentially less costly alternative to routine surgical biopsies. BioProtonics states that MRH could enable earlier detection of many diseases and cancers, allow more accurate therapies sooner in the disease cycle, improve patient outcomes, and lower medical costs. The MRH protocol is designed to integrate into a standard MRI exam with minimal impact on scan duration, adding as little as 90 seconds to the overall procedure. The data produced is fully compatible with DICOM protocols, supporting seamless integration with existing medical imaging workflows, data transfer, storage, and analysis across DICOM-compliant platforms and into the bioProtonics Cloud, where AI analytics are accessed. The company also describes advanced AI analysis that compares MRH data like a digital biopsy. BioProtonics is a privately held company. Its leadership team includes CEO Burton Tripathi, PhD, who has over two decades of leadership experience in developing disruptive technologies, leading commercialization efforts, and facilitating mergers and acquisitions, and who previously served as CEO of Beyeonics Vision. Timothy James, PhD, is the Chief Technology Officer and founder, with extensive experience in product innovation and business development in the MRI market. Other team members include Shu Zhang, PhD, an MRI physicist and imaging scientist specializing in quantitative MRI and diffusion; Ian Parker, PhD, VP of Research and Development, focused on MRI physics and data; Arthur Thomas, PhD, working on productization with over 30 years of experience at the intersection of informatics and life sciences, particularly artificial intelligence; Julia Huffman, who manages finance and administration; and Kyle Williams, a senior software engineer with experience in cybersecurity and medical devices. The company operates in the United States and is developing its MRH technology for clinical and research applications. Its official website serves as the primary source of information about its technology, team, and value proposition. As a relatively early-stage medical technology company, BioProtonics is focused on commercializing its MRH platform and establishing partnerships within the medical imaging ecosystem.

BioProtonics is a medical imaging technology company based in Santa Barbara, California. The company was founded by Timothy James, PhD, who serves as Chief Technology Officer. James has extensive experience in product innovation and business development within the MRI market, with a focus on matching technological possibilities with economic importance. The company has assembled a leadership team with deep expertise in MRI physics, software engineering, artificial intelligence, and business operations. The company's core technology, Magnetic Resonance Histopathology (MRH), is a novel MRI-based software method that non-invasively measures tissue texture at the micro level (sub 1mm). MRH uses a proprietary MRI pulse sequence that captures novel data about tissue microarchitecture by targeting specific spatial wavelengths, providing insight into tissue texture and structural differences for more accurate diagnosis. The technology is designed to be compatible with DICOM protocols, ensuring seamless integration with existing medical imaging workflows, and adds as little as 90 seconds to a standard MRI exam. The company also offers advanced AI analysis that compares MRH data like a digital biopsy, accessible via the bioProtonics Cloud. BioProtonics positions MRH as a valuable tool to help radiologists detect signs of early cancer or other diseases, potentially leading to a safer, less invasive, more accurate, and less costly alternative to routine surgical biopsies. The company believes this advancement could allow for earlier detection of many diseases and cancers, enable more accurate therapies sooner in the disease cycle, improve patient outcomes, and lower medical costs. As of the available information, BioProtonics is a privately held company. Its CEO is Burton Tripathi, PhD, who brings over two decades of leadership experience, specializing in developing disruptive technologies, leading commercialization efforts, and facilitating M&A. He previously served as CEO of Beyeonics Vision, where he raised over $12 million. Other key team members include Shu Zhang, PhD, an MRI physicist and imaging scientist with more than a decade of experience advancing MRI technologies for clinical and research applications, with a focus on quantitative MRI and diffusion; Ian Parker, PhD, VP of Research and Development, specializing in MRI physics and data; Arthur Thomas, PhD, who has over 30 years of experience at the boundary between informatics and the life sciences, with a particular emphasis on applications of artificial intelligence, and who was founder and CEO of Proteus Associates; Julia Huffman, who has managed business operations for small businesses throughout her career; and Kyle Williams, a senior software engineer with experience in cybersecurity and medical devices. The company operates in the United States and continues to develop and promote its MRH technology for clinical and research applications. Its official website provides detailed information about the technology, team, and value proposition.

Non-invasive digital biopsy using MRI to detect early stages of disease, positioned as a safer, less invasive, more accurate, and less costly alternative to surgical biopsies.

• Magnetic Resonance Histopathology (MRH)

  A novel MRI-based software method that non-invasively measures tissue texture at the micro level (sub 1mm) using a proprietary MRI pulse sequence targeting specific spatial wavelengths.

• bioProtonics Cloud

  A cloud platform where AI analytics for MRH data are accessed, compatible with DICOM protocols.

1. 1Home | bioProtonicsbioprotonics.com
2. 2Team (List) | bioProtonicsbioprotonics.com
3. 3BioProtonics - Wikidatawikidata.org